Remdesivir (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Remdesivir" in Italian language version.

refsWebsite

Global rank Italian rank

12doi.org

2^nd place

7^th place

9nih.gov

4^th place

9^th place

2oadoi.org

799^th place

22^nd place

2nature.com

234^th place

226^th place

1timesnownews.com

725^th place

8,135^th place

1thewire.in

1,507^th place

low place

1medscape.com

719^th place

799^th place

1medicalfacts.it

low place

1science.org

1,160^th place

2,091^st place

1oup.com

485^th place

613^th place

1sciencemag.org

857^th place

540^th place

1reuters.com

49^th place

129^th place

1fiercebiotech.com

low place

1nejm.org

2,374^th place

1,283^rd place

1nytimes.com

7^th place

19^th place

1ilgiornale.it

1,381^st place

53^rd place

1fda.gov

447^th place

644^th place

1medrxiv.org

low place

1gilead.com

low place

doi.org

dx.doi.org

D. Cahard, C. McGuigan e J. Balzarini, Aryloxy Phosphoramidate Triesters as Pro-Tides, in Mini Reviews in Medicinal Chemistry, vol. 4, n. 4, 2004, DOI:10.2174/1389557043403936.
Christopher McGuigan, Sarah A. Harris, Susan M. Daluge, Kristjan S. Gudmundsson, Ed W. McLean, Thimysta C. Burnette, Harry Marr, Richard Hazen, Lynn D. Condreay, Lance Johnson, Erik De Clercq e Jan Balzarini, Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency, in Journal of Medicinal Chemistry, vol. 48, n. 10, May 2005, pp. 3504–3515, DOI:10.1021/jm0491400, PMID 15887959.
(EN) Travis K. Warren, Robert Jordan e Michael K. Lo, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, in Nature, vol. 531, n. 7594, 2016-03, pp. 381–385, DOI:10.1038/nature17180. URL consultato il 1º aprile 2020.
(EN) Travis Warren, Robert Jordan e Michale Lo, Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates, in Open Forum Infectious Diseases, vol. 2, suppl_1, 1º dicembre 2015, DOI:10.1093/ofid/ofv130.02. URL consultato il 1º aprile 2020.
Michael Jacobs, Alison Rodger e David J. Bell, Late Ebola virus relapse causing meningoencephalitis: a case report, in Lancet (London, England), vol. 388, n. 10043, 30 luglio 2016, pp. 498–503, DOI:10.1016/S0140-6736(16)30386-5. URL consultato il 1º aprile 2020.
(EN) Timothy P. Sheahan, Amy C. Sims e Rachel L. Graham, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, in Science Translational Medicine, vol. 9, n. 396, 28 giugno 2017, DOI:10.1126/scitranslmed.aal3653. URL consultato il 1º aprile 2020.
(EN) Michelle L. Holshue, Chas DeBolt e Scott Lindquist, First Case of 2019 Novel Coronavirus in the United States, in New England Journal of Medicine, 31 gennaio 2020, DOI:10.1056/NEJMoa2001191. URL consultato il 1º aprile 2020.
(EN) Manli Wang, Ruiyuan Cao e Leike Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, in Cell Research, vol. 30, n. 3, 2020-03, pp. 269–271, DOI:10.1038/s41422-020-0282-0. URL consultato il 1º aprile 2020.
(EN) WHO Solidarity trial Consortium, Hongchao Pan e Richard Peto, Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results, 15 ottobre 2020, pp. 2020.10.15.20209817, DOI:10.1101/2020.10.15.20209817. URL consultato il 3 aprile 2022.
Niels C Pedersen, Michel Perron e Michael Bannasch, Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis, in Journal of Feline Medicine and Surgery, vol. 21, n. 4, 2019-4, pp. 271–281, DOI:10.1177/1098612X19825701. URL consultato il 1º aprile 2020.
Maria L. Agostini, Erica L. Andres e Amy C. Sims, Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease, in mBio, vol. 9, n. 2, 03 06, 2018, DOI:10.1128/mBio.00221-18. URL consultato il 1º aprile 2020.
Egor P. Tchesnokov, Joy Y. Feng e Danielle P. Porter, Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir, in Viruses, vol. 11, n. 4, 04 04, 2019, DOI:10.3390/v11040326. URL consultato il 1º aprile 2020.

fda.gov

(EN) Office of the Commissioner, FDA Approves First Treatment for COVID-19, su FDA, 22 ottobre 2020. URL consultato il 3 aprile 2022.

fiercebiotech.com

(EN) Gilead mulls repositioning failed Ebola drug in China virus, su FierceBiotech. URL consultato il 1º aprile 2020.

gilead.com

(EN) Gilead Sciences Statement on the Solidarity Trial, su gilead.com. URL consultato il 3 aprile 2022.

ilgiornale.it

Le buone notizie arrivano dallo Spallanzani: guariti il turista cinese e il ricercatore emiliano, su ilgiornale.it.

medicalfacts.it

Guido Silvestri, Coronavirus – Megapillolone di ottimismo: finalmente una buona notizia, su Medicalfacts, 30 aprile 2020. URL consultato il 30 aprile 2020.

medrxiv.org

(EN) WHO Solidarity trial Consortium, Hongchao Pan e Richard Peto, Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results, 15 ottobre 2020, pp. 2020.10.15.20209817, DOI:10.1101/2020.10.15.20209817. URL consultato il 3 aprile 2022.

medscape.com

Remdesivir Under Study as Treatment for Novel Coronavirus, su medscape.com.

nature.com

(EN) Travis K. Warren, Robert Jordan e Michael K. Lo, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, in Nature, vol. 531, n. 7594, 2016-03, pp. 381–385, DOI:10.1038/nature17180. URL consultato il 1º aprile 2020.
(EN) Manli Wang, Ruiyuan Cao e Leike Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, in Cell Research, vol. 30, n. 3, 2020-03, pp. 269–271, DOI:10.1038/s41422-020-0282-0. URL consultato il 1º aprile 2020.

nejm.org

(EN) Michelle L. Holshue, Chas DeBolt e Scott Lindquist, First Case of 2019 Novel Coronavirus in the United States, in New England Journal of Medicine, 31 gennaio 2020, DOI:10.1056/NEJMoa2001191. URL consultato il 1º aprile 2020.

nih.gov

ncbi.nlm.nih.gov

Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys, su ncbi.nlm.nih.gov.
Christopher McGuigan, Sarah A. Harris, Susan M. Daluge, Kristjan S. Gudmundsson, Ed W. McLean, Thimysta C. Burnette, Harry Marr, Richard Hazen, Lynn D. Condreay, Lance Johnson, Erik De Clercq e Jan Balzarini, Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency, in Journal of Medicinal Chemistry, vol. 48, n. 10, May 2005, pp. 3504–3515, DOI:10.1021/jm0491400, PMID 15887959.
(EN) Argentinian mammarenavirus, su ncbi.nlm.nih.gov. URL consultato il 30 aprile 2020.
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses, su ncbi.nlm.nih.gov.
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, su ncbi.nlm.nih.gov.
Michael Jacobs, Alison Rodger e David J. Bell, Late Ebola virus relapse causing meningoencephalitis: a case report, in Lancet (London, England), vol. 388, n. 10043, 30 luglio 2016, pp. 498–503, DOI:10.1016/S0140-6736(16)30386-5. URL consultato il 1º aprile 2020.
Niels C Pedersen, Michel Perron e Michael Bannasch, Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis, in Journal of Feline Medicine and Surgery, vol. 21, n. 4, 2019-4, pp. 271–281, DOI:10.1177/1098612X19825701. URL consultato il 1º aprile 2020.
Maria L. Agostini, Erica L. Andres e Amy C. Sims, Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease, in mBio, vol. 9, n. 2, 03 06, 2018, DOI:10.1128/mBio.00221-18. URL consultato il 1º aprile 2020.
Egor P. Tchesnokov, Joy Y. Feng e Danielle P. Porter, Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir, in Viruses, vol. 11, n. 4, 04 04, 2019, DOI:10.3390/v11040326. URL consultato il 1º aprile 2020.

nytimes.com

(EN) Amy Harmon, Inside the Race to Contain America’s First Coronavirus Case, in The New York Times, 5 febbraio 2020. URL consultato il 1º aprile 2020.

oadoi.org

D. Cahard, C. McGuigan e J. Balzarini, Aryloxy Phosphoramidate Triesters as Pro-Tides, in Mini Reviews in Medicinal Chemistry, vol. 4, n. 4, 2004, DOI:10.2174/1389557043403936.
Christopher McGuigan, Sarah A. Harris, Susan M. Daluge, Kristjan S. Gudmundsson, Ed W. McLean, Thimysta C. Burnette, Harry Marr, Richard Hazen, Lynn D. Condreay, Lance Johnson, Erik De Clercq e Jan Balzarini, Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency, in Journal of Medicinal Chemistry, vol. 48, n. 10, May 2005, pp. 3504–3515, DOI:10.1021/jm0491400, PMID 15887959.

oup.com

academic.oup.com

(EN) Travis Warren, Robert Jordan e Michale Lo, Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates, in Open Forum Infectious Diseases, vol. 2, suppl_1, 1º dicembre 2015, DOI:10.1093/ofid/ofv130.02. URL consultato il 1º aprile 2020.

reuters.com

(EN) Gilead working with China to test Ebola drug as new coronavirus treatment, in Reuters, 31 gennaio 2020. URL consultato il 1º aprile 2020.

science.org

(EN) The ‘very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug, su science.org. URL consultato il 3 aprile 2022.

sciencemag.org

stm.sciencemag.org

(EN) Timothy P. Sheahan, Amy C. Sims e Rachel L. Graham, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, in Science Translational Medicine, vol. 9, n. 396, 28 giugno 2017, DOI:10.1126/scitranslmed.aal3653. URL consultato il 1º aprile 2020.

thewire.in

Scientists Claim Drug Designed to Beat Ebola Also Fights Off Nipah, su thewire.in.

timesnownews.com

Experimental Ebola drug ‘remdesivir’ may help protect against Nipah virus, say scientists, su timesnownews.com.